Orthotopic Transplantation of Breast Tumors as Preclinical Models for Breast Cancer
May 18th, 2020
6.6K views
Patient-derived xenograft (PDX) models and transplantable genetically engineered mouse models faithfully recapitulate human disease and are preferred models for basic and translational breast cancer research. Here, a method is described to orthotopically transplant breast tumor fragments into the mammary fat pad to study tumor biology and evaluate drug response.
Overview
This protocol describes the orthotopic transplantation of breast tumor fragments into the mammary fat pad, providing valuable approaches for investigating tumor biology, drug responses, and mechanisms of drug resistance. This minimally invasive technique ensures proper placement of tumor tissues and maintains animal mobility.
Key Study Components
Area of Science
- Breast cancer research
- Transplantation techniques
- Drug response evaluation
Background
- Patient-derived xenograft (PDX) models recapitulate human disease.
- Orthotopic transplantation allows for better study of tumor biology.
- Minimally invasive techniques improve animal welfare.
- Multiple therapies can be evaluated simultaneously.
Purpose of Study
- To investigate tumor biology in a relevant model.
- To evaluate drug responses in breast cancer therapies.
- To understand mechanisms of drug resistance.
Methods Used
- Orthotopic transplantation of tumor fragments.
- Minimally invasive surgical techniques.
- Monitoring of tumor placement and animal mobility.
- Evaluation of multiple candidate therapies in preclinical trials.
Main Results
- Successful placement of tumor tissues within the mammary fat pad.
- Improved accessibility for counting and measurement.
- Ability to transplant multiple animals from a single patient-derived graft.
- Enhanced evaluation of drug responses compared to subcutaneous models.
Conclusions
- The described method is superior for establishing patient-derived models.
- It allows for comprehensive studies of tumor biology and therapy responses.
- Visualization techniques aid in ensuring successful procedures.
Frequently Asked Questions
What are patient-derived xenograft models?
Patient-derived xenograft (PDX) models are created by transplanting human tumor tissues into immunocompromised mice, allowing for the study of human cancer biology.
Why is orthotopic transplantation preferred?
Orthotopic transplantation closely mimics the natural environment of the tumor, providing more relevant biological insights compared to subcutaneous models.
What are the advantages of this transplantation technique?
This technique is minimally invasive, maintains animal mobility, and allows for simultaneous evaluation of multiple therapies.
How does this method improve drug response studies?
It provides a more accurate representation of tumor behavior and drug interactions in a living organism.
What challenges are associated with the procedure?
The main challenges include applying the right pressure during fat pad peeling and ensuring proper anatomical placement of the tissue fragment.
Can this method be used for other types of tumors?
While this protocol focuses on breast tumors, similar techniques can be adapted for other tumor types as well.
Executive Industry Relevance
Orthotopic transplantation of breast tumor fragments into the mammary fat pad provides a preclinical model that recapitulates human tumor heterogeneity and therapeutic response, addressing a critical need in breast cancer drug development. This approach supports mechanistic de-risking by enabling evaluation of drug responses and resistance mechanisms in a physiologically relevant context, improving predictive confidence in preclinical-to-clinical translation. The method facilitates parallel evaluation of multiple therapies, enhancing portfolio triage efficiency in early discovery pipelines.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Scientific Value: Enables interrogation of therapeutic hypotheses using patient-derived tumor fragments that maintain native heterogeneity and stromal interactions.
- Operational Value: Supports functional target validation by assessing tumor growth and drug response in an orthotopic microenvironment.
- Predictive Value: Improves target confidence by modeling human-like tumor biology and therapy response, reducing false positives in target selection.
Screening & Assay Development
- Scientific Value: Generates quantifiable tumor growth and metastasis readouts for dose-response and biomarker correlation studies.
- Operational Value: Standardizes tumor implantation via reproducible fat pad pocket technique, enabling high-throughput preclinical trial formats.
- Scalability: Allows transplantation of dozens of animals from a single patient-derived graft, supporting parallel evaluation of multiple candidate therapies.
Translational & Preclinical Research
- Translational Continuity: Models recapitulate human tumor pathology and drug response, facilitating biomarker discovery and mechanism-of-action studies.
- Preclinical Validation: Enables longitudinal monitoring of tumor growth and metastasis, supporting risk-adjusted advancement decisions.
- Mechanistic De-risking: Investigates drug resistance mechanisms through post-treatment tissue analysis (H&E, IHC) to inform combination therapy strategies.
Pipeline & Workflow Integration
The method integrates into the discovery continuum from target validation through lead identification to preclinical efficacy testing, providing a bridge between in vitro findings and in vivo validation.
- Discovery Biology: Supports hypothesis testing by maintaining tumor-stroma interactions critical for pathway clarification and target de-risking.
- Screening: Delivers assay-ready models with standardized implantation and quantitative tumor growth metrics for compound evaluation.
- Analytics: Enables measurement of tumor volume, metastasis incidence, and biomarker expression to compare therapeutic conditions.
- Translational Research: Connects to preclinical continuity through histopathological and immunohistochemical analysis of resected tumors.
- Enterprise Reuse: Establishes a reusable platform for serial passaging and therapy screening across multiple cancer therapeutics from a single patient sample.
Operational & Enterprise Impact
- Scientific Value: Enhances predictive confidence by modeling human tumor heterogeneity and therapeutic response in vivo.
- Operational Value: Ensures reproducibility through standardized surgical technique and postoperative monitoring protocols.
- Strategic Value: Improves go/no-go decisions by providing early efficacy and resistance data, reducing late-stage attrition risk.
- Portfolio Impact: Enables risk-adjusted prioritization of therapies based on orthotopic efficacy and resistance profiles.
Implementation Considerations
- Requires expertise in microsurgical techniques for fat pad dissection and tumor fragment implantation.
- Dependent on sterile surgical instrumentation, anesthesia monitoring, and postoperative animal care infrastructure.
- Necessitates cross-team standardization between surgical, oncology, and pathology teams for consistent tumor handling and analysis.
- Adaptation considerations include variability in tumor fragment viability and host strain immunocompromise levels.
- Practical limitations include tumor take rate variability and the need for technical training to ensure consistent pocket formation and fragment retention.
Biopharma FAQs
Why is fat pad pocket formation critical for tumor engraftment?
Proper fat pad pocket formation ensures secure placement of tumor fragments, preventing subcutaneous growth and enabling accurate assessment of orthotopic tumor biology and drug response.
How does tumor fragment size affect implantation success and growth kinetics?
One cubic millimeter fragments are used to balance viability and engraftment efficiency, supporting consistent tumor take rates and measurable growth for drug response evaluation.
What role does vascular cauterization play in fat pad preparation?
Cauterizing vessels medial to the lymph node prevents hemorrhage and stabilizes the fat pad pocket, ensuring reliable tumor fragment retention and minimizing surgical complications.
How is tumor placement validated post-implantation?
Tumor placement is confirmed by visualizing the fragment within the fat pad pocket and monitoring for growth, with palpation typically detectable two to eight weeks post-transplantation.
What analytical methods are used to assess tumor response post-treatment?
H&E staining evaluates tumor pathology, while immunohistochemistry monitors lineage-specific markers, cell viability, and functional status to assess drug effects and resistance mechanisms.
Chapters in this video
0:04
Introduction
1:22
Cryopreserved Mammary Tumor Fragment Preparation
2:23
Fresh Mammary Tumor Sample Collection and Preparation
3:28
Surgical Preparation
4:04
Tumor Fragment Transplantation
6:26
Results: Representative Transplant Tumor Characterization
6:54
Conclusion
